close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.575 -0.045 (-2.78%)
Streaming Delayed Price Updated: 11:12 AM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Forecasting The Future: 4 Analyst Projections For Ocugen
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Why Ocugen Stock Zoomed 12% Higher Today
A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs. 
Via The Motley Fool
Ocugen Shares Are Trading Higher Monday: What's Going On?
Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400. 
Via Benzinga
Demystifying Ocugen: Insights From 5 Analyst Reviews
 
Via Benzinga
A Peek at Ocugen's Future Earnings
 
Via Benzinga
A Look at Ocugen's Upcoming Earnings Report
 
Via Benzinga
Beyond The Numbers: 5 Analysts Discuss Ocugen Stock
 
Via Benzinga
Ocugen (OCGN) Q2 Revenue Jumps 20%
Via The Motley Fool
Ocugen Inc (NASDAQ:OCGN) Q2 2025 Earnings: Revenue Surges, EPS Loss Narrows
Ocugen Inc (OCGN) reports Q2 2025 earnings with $1.37M revenue, beating estimates by 284%, while EPS loss narrows to -$0.05. Progress in gene therapy trials boosts investor optimism. 
Via Chartmill
Earnings Scheduled For August 1, 2025
 
Via Benzinga
Expert Outlook: Ocugen Through The Eyes Of 4 Analysts
 
Via Benzinga
Navigating 4 Analyst Ratings For Ocugen
 
Via Benzinga
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?
Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics. 
Via Benzinga
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial
Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients who currently have no other options. 
Via Benzinga
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
A Preview Of Ocugen's Earnings
 
Via Benzinga
Peering Into Ocugen's Recent Short Interest
 
Via Benzinga
Why Ocugen (OCGN) Stock Is Falling
Ocugen shares are trading lower by 11% Thursday morning. The company announced the pricing of its public offering. 
Via Benzinga
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts
 
Via Benzinga
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish
CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three... 
Via Stocktwits
Topics Lawsuit
Earnings Scheduled For May 9, 2025
 
Via Benzinga
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates
Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years. 
Via Stocktwits
Ocugen (OCGN) Q4 2024 Earnings Call Transcript
OCGN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Earnings Scheduled For March 5, 2025
 
Via Benzinga
Ocugen (OCGN) Q3 2024 Earnings Call Transcript
OCGN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Ocugen (OCGN) Q2 2024 Earnings Call Transcript
OCGN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
These two stocks could have vastly different long-term performances. 
Via The Motley Fool
3 Penny Stocks That Could Turn $10K Into $100K in 3 Years
Discover three high-potential penny stocks that could derive 10X returns in biotechnology, silver and oil and gas storage and transportation. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today